Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Mateos, M.V. (María Victoria) | - |
dc.creator | Cibeira, M. (M.T.) | - |
dc.creator | Richardson, P.G. (Paul G.) | - |
dc.creator | Prosper-Cardoso, F. (Felipe) | - |
dc.creator | Oriol, A. (Albert) | - |
dc.creator | Rubia, J. (Javier) de la | - |
dc.creator | Lahuerta, J.J. (Juan José) | - |
dc.creator | García-Sanz, R. (Ramón) | - |
dc.creator | Extremera, S. (S.) | - |
dc.creator | Szyldergemajn, S. (Sergio) | - |
dc.creator | Corrado, C. (C.) | - |
dc.creator | Singer, H. (H.) | - |
dc.creator | Mitsiades, C.S. (Constantine S.) | - |
dc.creator | Anderson, K.C. (K.C.) | - |
dc.creator | Bladé, J. (Joan) | - |
dc.creator | San-Miguel, J.F. (Jesús F.) | - |
dc.date.accessioned | 2011-05-25T15:07:19Z | - |
dc.date.available | 2011-05-25T15:07:19Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | Mateos, M. V., Cibeira, M. T., Richardson, P. G., Prosper, F. et al.Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma.Clin Cancer Res (2010); 16 (12): 3260-3269 | es_ES |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://hdl.handle.net/10171/18157 | - |
dc.description.abstract | Purpose: This trial evaluated the antitumor activity and safety of the marine-derived cyclodepsipeptide plitidepsin in patients with relapsed/refractory multiple myeloma. Experimental Design: This was a prospective, multicenter, open-label, single-arm, phase II trial with plitidepsin at 5 mg/m2 as a 3-hour i.v. infusion every two weeks. The protocol was amended to allow patients with suboptimal response to single-agent plitidepsin to add 20 mg/day on days 1 to 4 of oral dexamethasone every two weeks. Results: Fifty-one patients started treatment with plitidepsin and 47 were evaluable for efficacy. The overall response rate (complete response plus partial response plus minimal response) was 13% with plitidepsin alone and 22% in the cohort of patients with the addition of dexamethasone (n = 19, 18 evaluable). Both plitidepsin alone and with dexamethasone were feasible and well tolerated. Anemia (29%) and thrombocytopenia (18%) were the most frequent grade 3/4 hematologic toxicities. Fatigue (16%), muscular toxicity (6%), and transient alanine aminotransferase/aspartate aminotransferase (27%) and creatine phosphokinase (23%) increases were the most relevant nonhematologic side effects. A prolonged plasma half-life was observed in responding patients as compared with nonresponding patients (P = 0.009). Conclusions: Single-agent plitidepsin has limited but reproducible activity in relapsed/refractory multiple myeloma patients. Activity observed after dexamethasone addition merits further study. Both regimens were well tolerated in this heavily pretreated population. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | American Association for Cancer Research | es_ES |
dc.rights | info:eu-repo/semantics/closedAccess | - |
dc.subject | Materias Investigacion::Ciencias de la Salud::Oncología | es_ES |
dc.title | Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | http://dx.doi.org/10.1158/1078-0432.CCR-10-0469 | es_ES |
Files in This Item:
There are no files associated with this item.
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.